Following on from information provided to NICE by the company in [Rheumatoid arthritis (active, treated) – sirukumab, the appraisal of October 2017 was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1002 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
| Companies sponsors | Janssen (sirukumab) |
| Others | Department of Health |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Arthritis Action |
| National Rheumatoid Arthritis Society | |
| Professional groups | British Society for Rheumatology |
| Primary Care Rheumatology Society | |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association | |
| Comparator companies | AbbVie |
| Accord Healthcare - (CAU not returned, not participating) | |
| Amdipharm Mercury - (CAU not returned, not participating) | |
| Biogen | |
| Bristol-Myers Squibb | |
| Concordia international - (CAU not returned, not participating) | |
| Eli Lilly | |
| Hameln pharmaceuticals - (CAU not returned, not participating) | |
| Hospira - (CAU not returned, not participating) | |
| medac - (CAU not returned, not participating) | |
| Merck Sharp & Dohme | |
| Napp | |
| Nordic Pharma - (CAU not returned, not participating) | |
| Orion Pharma - (CAU not returned, not participating) | |
| Pfizer | |
| Roche | |
| Rosemont Pharmaceuticals - (CAU not returned, not participating) | |
| Sandoz - (CAU not returned, not participating) | |
| UCB Pharma Limited | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in [Rheumatoid arthritis (active, treated) – sirukumab, the appraisal of October 2017 was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 30 October 2017 | Suspended. We have been informed by the company, Janssen, that it has decided to withdraw its marketing authorisation application for sirukumab. Consequently, we have suspended this appraisal. |
| 28 July 2017 | Invitation to participate |
| 25 April 2017 | Referral |
| 21 April 2017 | In progress. Topic referred |
| 03 January 2017 - 31 January 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual